Drilldown: Medicines

Other values:

Search

None (54) · Benzedrex (1) · Delysid (historical, Sandoz, withdrawn 1965) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

1-acetyl-LSD; prodrug of LSD (1) · 5-HT2A agonist; D2 partial agonist (1) · 5-HT2A partial agonist (1) · Adenosine receptor antagonist (1) · Adenosine receptor antagonist; dopaminergic (1) · Adenosine receptor antagonist; phosphodiesterase inhibitor (1) · Alpha-adrenergic agonist; monoamine releaser (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) · AMPA modulator; catecholaminergic (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Dopamine and serotonin reuptake inhibitor; actoprotector (1) · Dopamine reuptake inhibitor; tropane analogue (1) · Dopamine/norepinephrine reuptake inhibitor (5) · Indirect sympathomimetic; norepinephrine releaser (1) · LSD analogue; 5-HT2A agonist (4) · Lysergic acid 2,4-dimethylazetidide; 5-HT2A agonist (1) · Lysergic acid hydroxyethylamide; 5-HT2A agonist (1) · Monoamine releasing agent (8) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Monoamine releasing agent; active ingredient in khat (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Monoamine reuptake inhibitor; sodium channel blocker (1) · N-methyl analogue of 2-AI (1) · Nicotinic acetylcholine receptor agonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine releaser (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Norepinephrine–dopamine reuptake inhibitor (2) · Potent dopamine and norepinephrine reuptake inhibitor (1) · Potent dopamine/norepinephrine reuptake inhibitor (1) · Prodrug of LSD; 5-HT2A agonist (4) · Selective norepinephrine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1)

None · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' · '"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' · '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' · '"`UNIQ--vote-00000006-QINU`"' · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' · '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' · Preventive treatment of migraine in adults (episodic and chronic) · '"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' · Acute treatment of migraine with or without aura in adults · ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) · ADHD, narcolepsy · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024

Other values:

Search

None (56)

None (56)

None (56)

None (55) · Oral (1)

None (55) · 30–60 minutes (1)

None (55) · 8–12 hours (1)

None (55) · 3–5 hours (1)

None (55) · 70–90% (oral) (1)

None (55) · Not established (1)

None (55) · Schedule I (United States) (1)